Symptom burden for patients with metastatic colorectal cancer treated with first-line FOLFOX or FOLFIRI with and without bevacizumab in the community setting

Supportive Cancer Therapy

Volumn 4, Issue 4, 2007, Pages 233-240

  Fortner, Barry V ^a,b,c,d   Schwartzberg, Lee S ^b,c   Stepanski, Edward J ^b   Houts, Arthur C ^a,c  

^a Supportive Oncology Services   (United States)

^b Accelerated Community Oncology Research Network   (United States)

^c WEST CLINIC   (United States)

^d SOS/ACORN   (United States)

Author keywords

Community oncology; Neutropenia; Patient care monitor; Quality of life

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; APPETITE; ARTICLE; BREATHING DISORDER; BURN; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; COUGHING; DAYTIME SOMNOLENCE; DIARRHEA; DIZZINESS; DRY SKIN; DYSPHAGIA; DYSPNEA; FATIGUE; FEMALE; HAIR LOSS; HEADACHE; HUMAN; INCOME; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENTAL CONCENTRATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PAIN; PARANASAL SINUS DISEASE; PARESTHESIA; PATIENT CARE; PRURITUS; QUALITY OF LIFE; QUESTIONNAIRE; RASH; SEXUAL BEHAVIOR; SIDE EFFECT; SKIN TINGLING; SLEEP DISORDER; SORE THROAT; SWEATING; TASTE; TREATMENT OUTCOME; WEIGHT CHANGE; XEROSTOMIA;

EID: 35348931205     PISSN: 15432912     EISSN: None     Source Type: Journal    
DOI: 10.3816/SCT.2007.n.020     Document Type: Article

References (18)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43-66.
2. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10:896-903.
3. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group [see comments]. N Engl J Med 2000; 343:905-914.
4. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-1047.
5. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352:1407-1412.
6. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947.
7. Goldberg RM, Sargent DJ, Morton RF, et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup trial. J Clin Oncol 2006; 24:3347-3353.
8. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30.
9. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005; 23:4866-4875.
10. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-237.
11. Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer 2005; 5(suppl 1):S38-S46.
12. Former B, Baldwin S, Schwartzberg L, et al. Validation of the Cancer Care Monitor items for physical symptoms and treatment side effects using expert oncology nurse evaluation. J Pain Symptom Manage 2006; 31:207-214.
13. Former B, Okon T, Schwartzberg L, et al. The Cancer Care Monitor: psychometric content evaluation and pilot testing of a computer administered system for symptom screening and quality of life in adult cancer patients. J Pain Symptom Manage 2003; 26:1077-1092.
14. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004; 100:228-237.
15. Lyman GH, Kuderer NM. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol 2004; 50:129-146.
16. Savard J, Simard S, Ivers H, et al. Randomized study on the efficacy of cognitive-behavioral therapy for insomnia secondary to breast cancer, part I: sleep and psychological effects. J Clin Oncol 2005; 23:6083-6096.
17. Stepanski EJ, Rybarczyk B. Emerging research on the treatment and etiology of secondary or comorbid insomnia. Sleep Med Rev 2006; 10:7-18.
18. Fernandes R, Stone P, Andrews P, et al. Comparison between fatigue, sleep disturbance, and circadian rhythm in cancer inpatients and healthy volunteers: evaluation of diagnostic criteria for cancer-related fatigue. J Pain Symptom Manage 2006; 32:245-254.